Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -140.62% | -47.24% | -223.26% | -255.16% | -322.87% |
| Total Depreciation and Amortization | -59.12% | -41.04% | -16.13% | 7.63% | 21.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,640.14% | 264.63% | 193.81% | -0.91% | -19.11% |
| Change in Net Operating Assets | -96.26% | -93.78% | -33.60% | 44.94% | 416.35% |
| Cash from Operations | -44.00% | -64.19% | -341.49% | -483.94% | -292.00% |
| Capital Expenditure | 86.26% | -24.32% | -24.32% | -225.64% | -670.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -727.94% | -506.00% | -- | -- | -- |
| Cash from Investing | -724.45% | -504.67% | -309,440.54% | -299,397.44% | -179,617.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.51% | -96.13% | 112,199.07% | 233,849.51% | 207,581.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,084.13% | 3,711.12% | -245.43% | -765.55% | -- |
| Cash from Financing | -47.87% | -81.44% | 20.53% | 2,027.17% | 1,952.88% |
| Foreign Exchange rate Adjustments | -260.51% | -71.83% | -1,226.67% | -42.02% | 101.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.57% | -185.00% | -185.65% | 4,042.42% | 2,639.50% |